Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | OGA | O60502 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2572656 | 0.77 | ENPP2 (0.43) | ENPP2LOXL2LOXPTGS2KDM4E | |
| SCHEMBL1640713 | 0.77 | PTGS2 (0.56) | ENPP2PTGS2 | |
| SCHEMBL1642998 | 0.76 | ENPP2 (0.52) | ENPP2LOXL2LOXPTGS2KDM4E | |
| SCHEMBL12091515 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2 | |
| SCHEMBL5754599 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2KDM4E | |
| SCHEMBL564682 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2 | |
| SCHEMBL597932 | 0.76 | KDM4E (0.64) | ENPP2LOXL2LOXKDM4E | |
| SCHEMBL3599742 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2KDM4E | |
| SCHEMBL8313419 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2KDM4E | |
| SCHEMBL9881056 | 0.76 | ENPP2 (0.41) | ENPP2LOXL2LOXPTGS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2021-10-14 | — | — | US | disclosed |
| EP-3560925-B1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO LTD (JP) | 2021-06-02 | — | — | EP | disclosed |
| EP-3815687-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | Meiji Seika Pharma Co., Ltd. (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2020-06-02 | — | — | US | disclosed |
| EP-3560925-A1 | NOVEL COMPOUND AND PHARMACEUTICALLY-ACCEPTABLE SALT THEREOF | Meiji Seika Pharma Co., Ltd. (JP) | 2019-10-30 | — | — | EP | disclosed |
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2019-10-24 | — | — | US | disclosed |
| US-7754743-B2 | Heteroarylcarbamoylbenzene derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-07-13 | — | — | US | disclosed |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | MSD K.K. (JP) | 2009-01-15 | — | — | US | disclosed |
| US-7432287-B2 | Heteroarylcarbamoylbenzene derivative | BANYU PHARMECEUTICAL CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | MSD K.K. (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1600442-A1 | HETEROARYLCARBAMOYLBENZENE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190322686-A1 | NOVEL COMPOUND AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | REN, CYP11B1, CYP11B2 | ENPP2 3438/4885LOXL2 3618/4885LOX 2602/4885 |
| US-10669283-B2 | Compound and pharmacologically acceptable salt thereof | REN, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP11B2 | ENPP2 3953/4885LOXL2 3504/4885LOX 2670/4885 |
| US-20090018056-A1 | Heteroarylcarbamoylbenzene derivatives | GCK, GCKR, KHK | ENPP2 2663/4885LOXL2 2950/4885LOX 1139/4885 |
| US-20060167053-A1 | Heteroarylcarbamoylbenzene derivative | GCK, GCKR, GALK1 | ENPP2 2273/4885LOXL2 3054/4885LOX 1355/4885 |
| US-20210315892-A1 | THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES, AUTOIMMUNE DISEASES, FIBROTIC DISEASES, AND CANCER DISEASES | CCR1, SSB, C5 | ENPP2 155/4885LOXL2 884/4885LOX 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.